Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of cd40

Eduardo M. Sotomayor, Ivan M Borrello, Erev Tubb, Frédérique Marie Rattis, Harold Bien, Zhengbin Lu, Steve Fein, Stephen Schoenberger, Hyam I. Levitsky

Research output: Contribution to journalArticle

Abstract

Tumor antigen-specific T-cell tolerance limits the efficacy of therapeutic cancer vaccines. Antigen-presenting cells mediate the induction of T-cell tolerance to self-antigens. We therefore assessed the fate of tumor-specific CD4+ T cells in tumor-bearing recipients after in vivo activation of antigen-presenting cells with antibodies against CD40. Such treatment not only preserved the responsiveness of this population, but resulted in their endogenous activation. Established tumors regressed in vaccinated mice treated with antibody against CD40 at a time when no response was achieved with vaccination alone. These results indicate that modulation of antigen-presenting cells may be a useful strategy for enhancing responsiveness to immunization.

Original languageEnglish (US)
Pages (from-to)780-787
Number of pages8
JournalNature Medicine
Volume5
Issue number7
DOIs
StatePublished - Jul 1999

Fingerprint

T-cells
Antigen-Presenting Cells
Ligation
Tumors
T-Lymphocytes
Bearings (structural)
Chemical activation
Immunization
Neoplasms
Cancer Vaccines
Antibodies
Autoantigens
Neoplasm Antigens
Vaccination
Modulation
Therapeutics
Population

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Sotomayor, E. M., Borrello, I. M., Tubb, E., Rattis, F. M., Bien, H., Lu, Z., ... Levitsky, H. I. (1999). Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of cd40. Nature Medicine, 5(7), 780-787. https://doi.org/10.1038/10503

Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of cd40. / Sotomayor, Eduardo M.; Borrello, Ivan M; Tubb, Erev; Rattis, Frédérique Marie; Bien, Harold; Lu, Zhengbin; Fein, Steve; Schoenberger, Stephen; Levitsky, Hyam I.

In: Nature Medicine, Vol. 5, No. 7, 07.1999, p. 780-787.

Research output: Contribution to journalArticle

Sotomayor, EM, Borrello, IM, Tubb, E, Rattis, FM, Bien, H, Lu, Z, Fein, S, Schoenberger, S & Levitsky, HI 1999, 'Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of cd40', Nature Medicine, vol. 5, no. 7, pp. 780-787. https://doi.org/10.1038/10503
Sotomayor, Eduardo M. ; Borrello, Ivan M ; Tubb, Erev ; Rattis, Frédérique Marie ; Bien, Harold ; Lu, Zhengbin ; Fein, Steve ; Schoenberger, Stephen ; Levitsky, Hyam I. / Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of cd40. In: Nature Medicine. 1999 ; Vol. 5, No. 7. pp. 780-787.
@article{1622371ddce2486b8fde66f2c7d8e665,
title = "Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of cd40",
abstract = "Tumor antigen-specific T-cell tolerance limits the efficacy of therapeutic cancer vaccines. Antigen-presenting cells mediate the induction of T-cell tolerance to self-antigens. We therefore assessed the fate of tumor-specific CD4+ T cells in tumor-bearing recipients after in vivo activation of antigen-presenting cells with antibodies against CD40. Such treatment not only preserved the responsiveness of this population, but resulted in their endogenous activation. Established tumors regressed in vaccinated mice treated with antibody against CD40 at a time when no response was achieved with vaccination alone. These results indicate that modulation of antigen-presenting cells may be a useful strategy for enhancing responsiveness to immunization.",
author = "Sotomayor, {Eduardo M.} and Borrello, {Ivan M} and Erev Tubb and Rattis, {Fr{\'e}d{\'e}rique Marie} and Harold Bien and Zhengbin Lu and Steve Fein and Stephen Schoenberger and Levitsky, {Hyam I.}",
year = "1999",
month = "7",
doi = "10.1038/10503",
language = "English (US)",
volume = "5",
pages = "780--787",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of cd40

AU - Sotomayor, Eduardo M.

AU - Borrello, Ivan M

AU - Tubb, Erev

AU - Rattis, Frédérique Marie

AU - Bien, Harold

AU - Lu, Zhengbin

AU - Fein, Steve

AU - Schoenberger, Stephen

AU - Levitsky, Hyam I.

PY - 1999/7

Y1 - 1999/7

N2 - Tumor antigen-specific T-cell tolerance limits the efficacy of therapeutic cancer vaccines. Antigen-presenting cells mediate the induction of T-cell tolerance to self-antigens. We therefore assessed the fate of tumor-specific CD4+ T cells in tumor-bearing recipients after in vivo activation of antigen-presenting cells with antibodies against CD40. Such treatment not only preserved the responsiveness of this population, but resulted in their endogenous activation. Established tumors regressed in vaccinated mice treated with antibody against CD40 at a time when no response was achieved with vaccination alone. These results indicate that modulation of antigen-presenting cells may be a useful strategy for enhancing responsiveness to immunization.

AB - Tumor antigen-specific T-cell tolerance limits the efficacy of therapeutic cancer vaccines. Antigen-presenting cells mediate the induction of T-cell tolerance to self-antigens. We therefore assessed the fate of tumor-specific CD4+ T cells in tumor-bearing recipients after in vivo activation of antigen-presenting cells with antibodies against CD40. Such treatment not only preserved the responsiveness of this population, but resulted in their endogenous activation. Established tumors regressed in vaccinated mice treated with antibody against CD40 at a time when no response was achieved with vaccination alone. These results indicate that modulation of antigen-presenting cells may be a useful strategy for enhancing responsiveness to immunization.

UR - http://www.scopus.com/inward/record.url?scp=0032984347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032984347&partnerID=8YFLogxK

U2 - 10.1038/10503

DO - 10.1038/10503

M3 - Article

VL - 5

SP - 780

EP - 787

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 7

ER -